In contemporary SEP litigation, debates about FRAND almost always open with the same questions. What is the correct royalty rate? Which licences should count as comparables? Should the rate be global…
This week, I have the pleasure of speaking in Amsterdam at C5’s 19th Annual Forum on Pharma & Biotech Patent Litigation in Europe, in a panel devoted to running and defending preliminary…
"The readiness is all." - HamletSometimes a judgment does not change the melody of FRAND law. It changes the instrument through which that melody may be played. Not every player reads the same score…
This post is a continuation of the previous post published on July 25, 2025 and available here. Said post mentions case No. А40-315385/24 relating to osimertinib, in which the Russian pharmaceutical…
G 1/25 addresses a particularly controversial feature of EPO practice: the requirement to adapt the description. The long-anticipated hearing on G 1/25 took place on 8 May 2026, and unfolded in a…
"Gedanken ohne Inhalt sind leer, Anschauungen ohne Begriffe sind blind." — Immanuel Kant (Thoughts without content are empty, intuitions without concepts are blind.) Recent reactions to my…
Applications in the UPC for Requests to Produce Evidence under r.190 RoP are rare beasts. An Order following one such application was made on 14 April 2026 by the Brussels LD (full panel) in the case…
“Never interrupt your enemy when he is making a mistake.” — often attributed to Napoleon, and now, perhaps, to anyone still asking for a stay without a strategy.For years, European patent litigation…
I have long intended to write a piece about Artificial Intelligence (AI), but this seems to be one of these subjects where the world turns faster than my ability to process it. Nonetheless, here we…
As far as the authors are aware, there is, as yet, no dedicated blog to plant varieties. Therefore the following post has been prepared for the Kluwer Patents Blog in the expectation that some…
